SCHEMBL19865579

SCHEMBL19865579

Cc1ccc(N)cc1N1Cc2cnc(Cl)nc2N(C)C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 10/20 0.47
MAP4K2 Q12851 10/20 0.47
BMX P51813 10/20 0.47
ABL1 P00519 4/20 0.47
LCK P06239 1/20 0.47
FES P07332 1/20 0.47
RET P07949 1/20 0.47
PDGFRB P09619 1/20 0.47
KIT P10721 1/20 0.47
FGFR1 P11362 1/20 0.47
SRC P12931 1/20 0.47
PDGFRA P16234 1/20 0.47
FLT1 P17948 1/20 0.47
FGFR3 P22607 1/20 0.47
EPHA3 P29320 1/20 0.47
KDR P35968 1/20 0.47
EPHB4 P54760 1/20 0.47
TEK Q02763 1/20 0.47
KARS1 Q15046 1/20 0.47
NTRK3 Q16288 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23648843 0.87 TNK2 (0.44) TNK2MAP4K2BMXABL1LCK
SCHEMBL30018529 0.87 TNK2 (0.44) TNK2MAP4K2BMXABL1LCK
SCHEMBL23648389 0.85 TNK2 (0.45) TNK2MAP4K2BMXABL1LCK
SCHEMBL19922636 0.84 TNK2 (0.42) TNK2MAP4K2BMXABL1LCK
SCHEMBL4472920 0.81 FGFR1 (0.46) TNK2MAP4K2BMXABL1LCK
SCHEMBL23045888 0.81 TNK2 (0.47) TNK2MAP4K2BMXABL1LCK
SCHEMBL19865443 0.79 TNK2 (0.72) TNK2MAP4K2BMXABL1LCK
SCHEMBL30340763 0.77 FGFR4 (0.40) TNK2MAP4K2BMXABL1LCK
SCHEMBL3580202 0.76 FGFR4 (0.39) TNK2MAP4K2BMXABL1LCK
SCHEMBL31264954 0.76 FGFR4 (0.42) FGFR1FGFR3FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530221-B2 Pyrimido[4,5-d]pyrimidin-2-one derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-20 US disclosed
US-20210061810-A1 PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2021-03-04 US disclosed
US-10155767-B2 Therapeutic agent of acute myeloid leukemia containing 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-D]pyrimidine-2(1H)-one derivatives KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-12-18 US disclosed
US-10059717-B2 Urea compounds containing 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one skeleton as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-28 US disclosed
US-20180065970-A1 UREA COMPOUNDS CONTAINING 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE SKELETON AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-03-08 US disclosed
US-20180065970-A1 UREA COMPOUNDS CONTAINING 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE SKELETON AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-03-08 US disclosed
US-20180065969-A1 THERAPEUTIC AGENT OF ACUTE MYELOID LEUKEMIA CONTAINING 1,3,7-TRISUBSTITUTED 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDINE-2(1H)-ONE DERIVATIVES KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-03-08 US disclosed
US-20180065970-A1 UREA COMPOUNDS CONTAINING 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE SKELETON AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-03-08 US disclosed
WO-2018030800-A1 UREA COMPOUND HAVING 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDINE-2(1H)-ONE SKELETON HAVING PROTEIN KINASE INHIBITING ACTIVITY 한국과학기술연구원 2018-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530221-B2 Pyrimido[4,5-d]pyrimidin-2-one derivatives as protein kinase inhibitors LCK, CDK2, CDK5 TNK2 53/4885MAP4K2 82/4885BMX 1092/4885
US-10155767-B2 Therapeutic agent of acute myeloid leukemia containing 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-D]pyrimidine-2(1H)-one derivatives GAK, DCK, NRAS TNK2 38/4885MAP4K2 50/4885BMX 592/4885
US-20180065969-A1 THERAPEUTIC AGENT OF ACUTE MYELOID LEUKEMIA CONTAINING 1,3,7-TRISUBSTITUTED 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDINE-2(1H)-ONE DERIVATIVES GAK, DCK, NRAS TNK2 38/4885MAP4K2 50/4885BMX 592/4885
US-20210061810-A1 PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS LCK, CDK2, CDK5 TNK2 86/4885MAP4K2 90/4885BMX 1010/4885
US-10059717-B2 Urea compounds containing 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one skeleton as protein kinase inhibitors MAP4K2, CMPK1, MTOR TNK2 230/4885MAP4K2 1/4885BMX 1107/4885
US-20180065970-A1 UREA COMPOUNDS CONTAINING 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE SKELETON AS PROTEIN KINASE INHIBITORS MAP4K2, CMPK1, MTOR TNK2 230/4885MAP4K2 1/4885BMX 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.